Fibrin-derived peptide Bβ15-42 (FX06) as salvage treatment in critically ill patients with COVID-19-associated acute respiratory distress syndrome

Adam, Elisabeth H.; Schmid, Benedikt; Sonntagbauer, Michael; Kranke, Peter; Zacharowski, Kai; Meybohm, Patrick

doi:10.1186/s13054-020-03293-8

Critical Care

Table 1 Demographics and clinical characteristics at admission and treatment of patients

From: Fibrin-derived peptide Bβ15-42 (FX06) as salvage treatment in critically ill patients with COVID-19-associated acute respiratory distress syndrome

	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5	Patient 6
Age (Y)	52	78	63	51	71	55
Sex	Male	Male	Male	Female	Male	Male
BMI	31	35	26	54	28	37
Comorbidities	Obesity	Obesity, coronary artery disease, arterial hypertension	Bronchial asthma	Obesity, arterial hypertension, rheumatoid arthritis	Type 2 diabetes mellitus	Obesity, arterial hypertension
Invasive ventilation	Yes	Yes	Yes	Yes	Yes	Yes
Severity of ARDS at admission	Moderate	Moderate	Moderate	Moderate	Severe	Moderate
Anti-infective therapy	Imipeneme	Imipeneme	Imipeneme, voriconazol	Piperacillin/tazobactam, ciprofloxa-cin, meropenem, vancomycin, anidulafun-gin	Merope-neme, co-trimoxazol	Ampicillin/sulbactam, cephazolin, caspofungin
Days on ICU prior to FX06 treatment	0	3	4	10	15	2
SAPS II Score	57	75	43	68	63	59
P_aO₂/F_iO₂ ratio at admission	186	141	131	154	85	122
Daily dose of FX06	500 mg	600 mg	400 mg	400 mg	400 mg	400 mg
Duration of FX06 treatment (days)	7	7	4	3	4	4
vv-ECMO therapy	Yes	No	Yes	Yes	Yes	Yes
Outcome	Rehabilitation care (after 35 days)	Death	Rehabilitation care (after 70 days)	Death	Rehabilitation care (after 48 days)	Rehabilitation care (after 44 days)
Laboratory results at admission							Reference range
White blood cell count (cells per 10⁶/L)	14.02	15.56	6.26	7.9	14.2	11.2	3.92–9.81
Lymphocyte (cells per 10⁶/L)	1.12	1.24	0.71	0.92	1.44	1.32	1.05–3.24
Platelets	320	147	171	161	272	255	146–328
LDH U/L	378	1277	417	611	516	609	< 248
Creatinine mg/dL	0.72	2.34	0.43	0.50	0.82	0.88	0.7–1.2
C-reactive protein (mg/dL)	20.13	18.08	8.00	15.64	18.09	24.85	< 0.5
Ferritin ng/mL	883	5505	3708	1114	4079	3503 (day 3)	18–360
Procalcitonin ng/mL	0.15	0.30	0.78	0.09	1.32	2.44	< 0.5
Lactate mg/dL	9.0	14	9.0	8.1	12.6	13.5	4.5–14.5
IL-6 pg/mL	92.3	25.4	250	2647.0	440.9	360.1	< 7
D-dimer ng/mL	629	130,100	1056	450	2850	3750	< 500
aPTT (s)	28	30	29	48.6	44.0	37.8	25–37
vWF AG (%)	283	446	311	n/a	> 150	> 150	60–150

Demographics and clinical characteristics at admission and treatment of patients
Y years, BMI body mass index, ARDS acute respiratory distress syndrome, SAPS simplified acute physiology score, LDH lactate dehydrogenase, U units, aPTT activated partial Thromboplastin time, VWF AG von Willebrand factor antigen, SAPS II Simplified Acute Physiology Score, P_aO₂ partial pressure arterial oxygen, F_iO₂ fraction of inspired oxygen, vv veno-venous, ECMO extracorporeal membrane oxygenation

Back to article page

ISSN: 1364-8535

Contact us

Submission enquiries: journalsubmissions@springernature.com